361 Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

361 Capital’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	$956K	Sell	1,533 -922	-38%	-$523K	0.45%	52
2020 Q1	$1.2M	Buy	2,455 +963	+65%	+$397K	0.54%	37
2019 Q4	$560K	Buy	1,492 +170	+13%	+$57.2K	0.16%	261
2019 Q3	$367K	Buy	+1,322	New	+$391K	0.07%	302
2019 Q2	–	Sell	-3,300	Closed	-$1.35M	–	372
2019 Q1	$1.35M	Sell	3,300 -84	-2%	-$34.6K	0.24%	183
2018 Q4	$1.26M	Buy	+3,384	New	+$1.24M	0.26%	187
2018 Q2	–	Sell	-6,208	Closed	-$2.14M	–	380
2018 Q1	$2.14M	Buy	+6,208	New	+$2.16M	0.53%	36
2017 Q4	–	Sell	-2,337	Closed	-$1.04M	–	292
2017 Q3	$1.04M	Buy	+2,337	New	+$1.11M	0.2%	181

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Polen Capital Management Boca Raton, Florida $14.5B AUM 5.7% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

361 Capital's REGN Position: Q2 2020 in Review

361 Capital reduced its Regeneron Pharmaceuticals (REGN) stake by 38% in Q2 2020, selling an estimated $523K and leaving 1,533 shares worth $956K. The position accounts for 0.45% of the portfolio, ranked #52.

361 Capital first reported a position in REGN in Q3 2017 and has held it in 8 quarters since. The position peaked at $2.14M in Q1 2018. 932 funds tracked by Wall St. Rank hold REGN as of Q2 2020.

361 Capital held 1,533 shares of Regeneron Pharmaceuticals worth $956K as of Q2 2020.
361 Capital sold 922 Regeneron Pharmaceuticals shares in Q2 2020, an estimated $523K.
Regeneron Pharmaceuticals made up 0.45% of 361 Capital's portfolio in Q2 2020, its #52 holding.
361 Capital first reported a position in Regeneron Pharmaceuticals in Q3 2017 and has held it in 8 quarters since.
361 Capital's Regeneron Pharmaceuticals position peaked at $2.14M in Q1 2018.
932 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2020.

Based on 361 Capital's 13F filing for Q2 2020, filed 14 Aug 2020.